Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza

@article{Bae2020PyronaridineAA,
  title={Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza},
  author={Joon-Yong Bae and Gee Eun Lee and Heedo Park and Juyoung Cho and Yung-Eui Kim and Joo-Yeon Lee and Chung Ju and Wonki Kim and Jin Kim and Man-Seong Park},
  journal={bioRxiv},
  year={2020}
}
Since the first human case was reported in Wuhan Province, China in December 2019, SARS-CoV-2 has caused millions of human infections in more than 200 countries worldwide with an approximately 4.01% case-fatality rate (as of 27 July, 2020; based on a WHO situation report), and COVID-19 pandemic has paralyzed our global community. Even though a few candidate drugs, such as remdesivir (a broad antiviral prodrug) and hydroxychloroquine, have been investigated in human clinical trials, their… 
Pyronaridine Protects Against SARS-CoV-2 in Mouse
TLDR
Pyronaridine, an antiviral drug with in vitro activity against Ebola, Marburg and SARS-CoV-2 has now statistically significantly reduced the viral load in mice along with IL-6, TNF-α, and IFN-β ultimately demonstrating a protective effect against lung damage by infection to provide a new potential treatment for testing clinically.
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms
TLDR
Tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively and novel insights are provided into the mechanism of these compounds which is likely lysosomotropic.
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
TLDR
11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, cl ofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms
TLDR
Tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively and novel insights are provided into their mechanism which is likely lysosomotropic.
Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants
TLDR
Artemisia annua extracts inhibit SARS-CoV-2 infection, and the active component(s) in the extracts is likely something besides artemisinin or a combination of components that block virus infection at a step downstream of virus entry.
Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants
TLDR
Hot-water leaf extracts based on artemisinin, total flavonoids, or dry leaf mass showed antiviral activity with IC50 values of 0.1-8.7 μM, 0.01-0.14 μg, and 23.4-57.4 μg, respectively, while all hot water extracts were effective, and the active component(s) in the extracts is likely something besides art Artemisinin and total Flavonoids.
Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review
TLDR
A review of potential anti-COVID-19 therapeutics that block/inhibit the post-entry stages of the viral life cycle and their anti-inflammatory/immune-modulatory effects aimed at catalyzing their potential effective use in fighting the pandemic.
The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time
TLDR
Remdesivir, tocilizumab, and dexamethasone are some of the treatment options that have shown the most promise, but further randomized trials are required to particularly address timing and dosages to confidently create standardized protocols.
Repurposing Antimalarials to Tackle the COVID-19 Pandemic
TLDR
There is now sufficient evidence for ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.
Artemisia annua and artemisinins are ineffective against human Babesia microti and six Candida sp
TLDR
Results show that artemisinin, its derivatives, and A. annua are ineffective against B. microti and at least six species of Candida.
...
1
2
...

References

SHOWING 1-10 OF 11 REFERENCES
Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection
TLDR
Studies with pyronaridine clearly demonstrate potential utility for its repurposing as an antiviral against EBOV and merits further study in larger animal models with the added benefit of already being used as a treatment against malaria.
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
TLDR
The possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle are discussed, which could lead to new therapies able to counter the most severe effects of the disease.
The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.
TLDR
It is demonstrated that the efficacy of the antiviral effect of ART is augmented by co-treatment of HCMV-infected fibroblasts with ferrous iron, i.e. Ferrosanol, and/or the iron transfer-mediating molecule holo-transferrin, suggesting that ART might be able to prevent pro-inflammatory effects of infection.
The antiviral activities of artemisinin and artesunate.
TLDR
Analysis of the complete profile of the pharmacological activities and molecular modes of action of artemisinin and artesunate and their performance in clinical trials will further elucidate the full antimicrobial potential of these versatile pharmacological tools from nature.
Repurposing Pyramax® for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate
TLDR
It is demonstrated in vitro that pyronaridine tetraphosphate is an inhibitor of Lysotracker accumulation in lysosomes and may represent a unique example of the repurposing of a combination product for another disease.
In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
TLDR
These findings provide substantial evidence that AL and ASAQ are highly efficacious for the treatment of uncomplicated malaria in children in Burkina Faso and advocate the need to regularly replicate such surveillance studies.
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  • V. Corman, O. Landt, +21 authors C. Drosten
  • Computer Science, Medicine
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  • 2020
TLDR
A validated diagnostic workflow for 2019-nCoV is presented, its design relying on close genetic relatedness of 2019- nCoV with SARS coronavirus, making use of synthetic nucleic acid technology.
Artesunate Protects Against Sepsis-Induced Lung Injury Via Heme Oxygenase-1 Modulation
TLDR
Findings suggest an effective and applicable treatment to sepsis-induced lung injury and provide new insights into the molecular mechanisms and actions of artesunate.
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
TLDR
Patients who received hydroxychloroquine for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTC.
additivity of the lysosomotropic pyronaridine and non-lysosomotropic artesunate (preprint)
  • bioRxiv https://doi.org/10.1101/2020.04.25.061333
  • 2020
...
1
2
...